Cohance Lifesciences has received a Form FDA 483 containing four observations from United States Food and Drug Administration (USFDA) for its formulation (FDF) plant located at Shamshabad, Telangana. The USFDA conducted an inspection of the said plant from August 27 to September 4 , 2026 and the inspection was concluded with the issuance of a Form FDA 483.
Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.
